Targeting polymorphonuclear myeloid-derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy

Abstract

Tumor-driven immune suppression is a critical mechanism by which cancer cells evade the host immune system, leading to tumor growth and metastasis. The tumor immune microenvironment contains a large population of immune-suppressing myeloid cells, which play a key role in tumor development and drug resistance to existing immunotherapy. Polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) are important components of the immunosuppressive microenvironment. Uncovering the molecular mechanisms of PMN-MDSCs and finding specific targets for PMN-MDSCs to regulate tumor immune microenvironment is the focus and challenge of current immunotherapy. In a recent issue of Nature, Wang and colleagues revealed that CD300ld on PMN-MDSCs is required for tumor-driven immune suppression, this provided a new target for cancer immunotherapy, The study identified CD300ld as a novel, highly conserved tumor immunosuppressive receptor. CD300ld is highly expressed specifically on PMN-MDSCs and is a key receptor in regulating the recruitment and immunosuppressant function of PMN-MDSCs. Targeting CD300ld can reshape the tumor immune microenvironment by inhibiting the recruitment and function of PMN-MDSCs, resulting in broad-spectrum anti-tumor effects. CD300ld target shows good safety, conservation, anti-tumor effectiveness, and synergism with the Programmed death-1 target, which is expected to become a new ideal target for tumor immunotherapy.

References

1	C Wang, X Zheng, J Zhang, et al. CD300ld on neutrophils is required for tumour-driven immune suppression. Nature. 2023;621(7980):830-839.
2	Y Li, C Wang, Z Lu, M Luo. Targeting PMN-MDSCs via CD300ld receptor for cancer immunotherapy. Clin Transl Med. 2024;14(1):e1534.
3	E Hawila, H Razon, G Wildbaum, et al. CCR5 directs the mobilization of CD11b(+)Gr1(+)Ly6C(low) polymorphonuclear myeloid cells from the bone marrow to the blood to support tumor development. Cell Rep. 2017;21(8):2212-2222.
4	F Veglia, VA Tyurin, M Blasi, et al. Fatty acid transport protein 2 reprograms neutrophils in cancer. Nature. 2019;569(7754):73-78.
5	Z Chen, X Zhang, Z Xing, et al. OLFM4 deficiency delays the progression of colitis to colorectal cancer by abrogating PMN-MDSCs recruitment. Oncogene. 2022;41(22):3131-3150.